Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.09.22.509040Source: DataRank Database

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2022). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: greenTopics (3)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (32)

Sameer Kumar Malladi ORCID,Julian Q. Zhou ORCID,Zhuoming Liu ORCID,Baoling Ying,Wooseob Kim ORCID

Live enrichment

PubMed:19162232

National Institutes of Health

Grant: 1U01AI150747-01

DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES

National Institutes of Health

Grant: 5U01AI144616-02

DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity

National Institutes of Health

Grant: 5R01AI157155-02

Human antibody-based countermeasures against the Coronavirus SARS-CoV-2

National Institutes of Health

Grant: 2U01AI141990-06

Programming Durable Immune Responses To Vaccination

National Institutes of Health

Grant: 5R01AI163019-05

Mechanism and Inhibition of SARS-CoV-2 Entry

National Institutes of Health

Grant: 1R01AI168178-01

Structural interrogation of vaccine- and infection-induced B cell responses

greenLicense: cc-by-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2022/09/22/2022.09.22.509040.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2022.09.22.509040

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9516848

https://doi.org/10.1101/2022.09.22.509040

https://pubmed.ncbi.nlm.nih.gov/36172127

Fields of Study

0301 basic medicine03 medical and health sciences

Keywords

Article

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (10)

Use of Transient Transfection for cGMP Manufacturing of eOD-GT8 60mer, a Self-Assembling Nanoparticle Germline-Targeting HIV-1 Vaccine Candidate

bioRxiv (Cold Spring Harbor Laboratory)(2022)

co-citedsame journal

10.1101/2022.09.30.510310

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

N/A

1.2DataRank · unranked

Nucleic Acids Research(2020)

co-cited

10.1093/nar/gkaa379

CD8+ T cells in HIV control, cure and prevention

N/A

0.861DataRank · unranked

Nature reviews. Immunology(2020)

co-cited

10.1038/s41577-020-0274-9

Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo

Immunity(2020)

co-cited

10.1016/j.immuni.2020.08.001

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

N/A

0.773DataRank · unranked

Nature Medicine(2020)

co-cited

10.1038/s41591-020-0858-8

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

N/A

0.734DataRank · unranked

Scientific Reports(2020)

co-cited

10.1038/s41598-020-74949-2

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

N/A

2.7DataRank · unranked

The Lancet HIV(2020)

co-cited

10.1016/s2352-3018(20)30229-0

Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers

The Journal of Experimental Medicine(2020)

co-cited

10.1084/jem.20201254

Normal human lymph node T follicular helper cells and germinal center B cells accessed via fine needle aspirations

Journal of Immunological Methods(2020)

co-cited

10.1016/j.jim.2020.112746

In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity

Advanced Science(2020)

co-cited

10.1002/advs.201902802